M&A TermsEnsysce Biosciences and Signature Therapeutics are pleased to announce completion of a formal merger on Dec. 31, 2015, naming Dr. Lynn Kirkpatrick as CEO. The company will retain the name of Ensysce Biosciences and will be relocating to San Diego, California. Financial terms of the transaction were not disclosed.